Huiyi Technology Secures $30 Million Series C Funding Led by Qiming Venture Partners to Advance AI-Driven Healthcare Quality Control

VCBeat (WeChat ID: vcbeat) has learned that Beijing Huimei Cloud Technology Co., Ltd. (hereinafter referred to as “Huimei Technology”), a company deeply engaged in the field of medical artificial intelligence, has announced the completion of its Series C financing round amounting to $30 million. The round was led by Qiming Venture Partners, a prestigious firm in China’s venture capital industry, with participation from WuXi AppTec Venture Capital Fund and Huimei Capital.

It is reported that Huimei Technology’s early investor was Hillhouse Capital, which focuses on long-term value investment. The introduction of new investors this time aims to bring more diversified resources and a broader perspective to the company.

“We are delighted to have the opportunity to invest in Huimei Technology. We have been actively seeking investment opportunities that leverage technology to enhance the quality of healthcare services. Huimei’s knowledge and understanding of the latest clinical diagnosis and treatment, combined with its AI-driven capabilities in technology development and translation, will help improve both the quality and efficiency of healthcare delivery. The team, led by Zhang Qi, has demonstrated a long-term commitment to this significant mission, and we will support them in gradually turning this vision into reality,” said Hu Xubo, Managing Partner at Qiming Venture Partners.

Mr. Hu Zhengguo, Co-CEO of WuXi AppTec, stated: “WuXi AppTec focuses on investments in cutting-edge technologies and is actively building an innovation ecosystem for healthcare. Huimei Technology effectively improves the medical service ecosystem by integrating advanced AI technology with medical diagnostic expertise. We believe that investing in Huimei Technology will further enhance WuXi AppTec’s capacity to support medical innovation, accelerating our efforts to empower physicians and hospitals and ultimately benefit patients.”

“Zhang Qi’s team has carved out a significant niche in the field of medical artificial intelligence within just a few years, establishing a closed-loop product ecosystem that spans from clinical practice to healthcare quality management. This provides clinicians and hospital administrators with practical and effective tools to enhance quality and improve patient safety. Innovation creates value, and this represents the best practice of Huimei Medical Group in empowering traditional healthcare concepts through technology,” stated Luo Rushu, CEO of Huimei Medical Group and Managing Partner of Huimei Capital.

As a vertical healthcare fund under Hillhouse Capital Group, Huimei Capital leverages Hillhouse’s extensive footprint in the healthcare sector and the industrial operations of Huimei Medical Group to make multi-dimensional, comprehensive investments across the healthcare ecosystem, with the aim of accelerating the growth of early-stage and growth-stage pharmaceutical companies.

Leveraging technological strengths to address the “empirical medicine gaps” in traditional healthcare services, thereby bringing greater standardization and a sense of security to the industry. Zhang Qi, Founder and CEO of the company, stated when discussing the original intention behind starting the venture: “Healthcare is a highly specialized and unique sector, where safety and efficacy remain the enduring foundations of medical services. However, in actual clinical practice, quality management and patient safety assurance often lag behind, as traditional management approaches are no longer adequate for meeting the demands of highly specialized disease diagnosis and treatment processes. By integrating big data processing technologies, natural language processing capabilities, and computer-executable clinical medical logic, it is possible to effectively identify quality defects caused by human errors during the medical care process.”

It is understood that the company focuses on building an “AI-based medical quality control system.” After completing its Series C financing, Huimei Technology will continue to deepen its product research and development, further strengthening the competitive moat of its medical AI products with Dr. Mayson as the core brand.

Zhang Qi emphasized that the cornerstone of AI’s clinical application lies in medical knowledge graphs. To this end, the company has assembled a full-time team of over 30 physicians, including more than 10 senior doctors from renowned hospitals such as Peking University First Hospital and Sir Run Run Shaw Hospital of Zhejiang University School of Medicine. By co-building more comprehensive and specialized knowledge bases with leading specialties at tertiary Grade A hospitals, they continuously iterate and update the Huimei Knowledge Graph. This effort lays a solid “foundation” for the “superstructure” of AI applications, enabling the expansion from a general practice knowledge base to an AI product suite that includes advanced Clinical Decision Support Systems (CDSS), single-disease process quality control systems, intelligent VTE prevention and treatment systems, perioperative decision support systems, medical record quality control systems, and specialty-specific datasets. Ultimately, this establishes a closed-loop system for clinical quality management covering the entire diagnosis and treatment process.

Clinical Decision Support System (CDSS) is one of Huimei Technology’s earliest deployed and most mature products in clinical settings. With the national government vigorously promoting the informatization of electronic medical records, and large hospitals facing growing demands for the storage and analysis of massive datasets, CDSS has become an indispensable functional module within health information systems. Its key advantage lies in integrating standardized electronic clinical pathways with clinical workflows, thereby assisting clinicians in formulating more personalized and effective diagnostic and treatment decisions based on changes in patients’ conditions. This has driven the continuous expansion of CDSS applications into outpatient departments, emergency rooms, and inpatient wards at major hospitals.

“Tailored to the distinct requirements of various diagnostic and treatment processes in large hospitals, we have developed functionalities for different terminals used by physicians, nurses, and medical technologists, comprehensively enhancing the efficiency and intelligence level of clinical care,” introduced Zhang Qi. As a key component in the National Electronic Medical Record (EMR) Grading Evaluation, Huimei CDSS meets the criteria for high-level national assessments. It has already assisted more than 20 hospitals in achieving Level 6/5 in the National EMR Application Proficiency Grading Evaluation and Level 5-Yi/4-Jia in the Interconnectivity Standard Maturity Assessment, establishing itself as a leading pioneer in the construction of smart hospitals.

Among its partners are more than 60 renowned hospitals, including Shanghai Ruijin Hospital, Jiangsu Province People’s Hospital, Xuanwu Hospital of Capital Medical University, China-Japan Friendship Hospital, The Affiliated Hospital of Qingdao University, Henan Provincial People’s Hospital, China-Japan Union Hospital of Jilin University, and Wuhan Asia Heart Hospital, solidifying Huimei AI’s leading position in the industry.

Any product development is inevitably driven by core needs and guided by policy trends. In light of current issues in medical quality management and evaluation—such as incompleteness, discontinuity, non-standardization, and insignificant improvement effects—Huimei launched its Single-Disease Process Quality Control Management System at the end of last year. This system references the National Health Commission’s quality control requirements for specific (single) diseases, leveraging AI to automatically assess the rationality and compliance of diagnostic and therapeutic behaviors, while continuously monitoring clinical execution outcomes based on objective quality indicators.

This represents another valuable application of Huimei AI in the healthcare sector. By leveraging automated monitoring and intelligent alerts, it significantly reduces oversights in manual quality control, thereby enhancing guideline adherence and standardization in clinical diagnosis and treatment.

Meanwhile, AI can objectively compile statistics, perform real-time analysis, and visually present quality control outcomes. While manual statistical analysis of quality control data typically takes several to tens of minutes, machine computing operates at the millisecond level. This helps mitigate the lag and delays inherent in traditional manual retrospective medical record sampling and reduces labor input. Furthermore, integrating quality control results with performance evaluations ensures that quality improvement initiatives are effectively implemented.

This is the best era for AI, with the industry flourishing through diverse innovation and vigorous competition. Zhang Qi emphasized that the greatest pitfall for artificial intelligence is an overemphasis on technology alone. Whether in the present or the long term, the core of medical AI lies in its application. Only through the continuous accumulation, integration, and qualitative transformation of clinical applications and feedback can medical AI ultimately ride the next “wave of opportunity.”